David Schnell, M.D., is a co-founder and Managing Director of Prospect Venture Partners. See sector focus and contact routes.
David Schnell, M.D., is a co-founder and Managing Director of Prospect Venture Partners, a Palo Alto-based venture capital firm he established in 1997 after departing Kleiner Perkins Caufield & Byers. The firm focuses exclusively on life sciences, investing in biotechnology, medical devices, and healthcare technology across early- and late-stage companies, including public entities. Initial fund documentation indicated typical investments of $3 million to $5 million per company, with the firm acting as a lead investor in these rounds. Notable portfolio companies include Amicus Therapeutics (NASDAQ: FOLD), a biopharmaceutical firm, and Panmira Pharmaceuticals LLC, where Schnell serves as a Director. Schnell’s distinctive point of view centers on building biomedical companies with proprietary products and innovative technology led by outstanding entrepreneurial teams. His background as a physician (M.D.) complements the firm’s sole focus on health care and biomedical investing.
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in Palo Alto.
Investors like David Schnell · Full investor directory · Investor access · Company funding database